• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于时空步态参数的多发性硬化行走量表 12 评分的进一步验证。

Further validation of multiple sclerosis walking scale-12 scores based on spatiotemporal gait parameters.

机构信息

Department of Kinesiology and Community Health, University of Illinois at Urbana-Champaign, Urbana, IL 61801, USA.

出版信息

Arch Phys Med Rehabil. 2013 Mar;94(3):575-8. doi: 10.1016/j.apmr.2012.08.214. Epub 2012 Sep 5.

DOI:10.1016/j.apmr.2012.08.214
PMID:22960049
Abstract

OBJECTIVE

To examine the association between Multiple Sclerosis Walking Scale-12 (MSWS-12) scores and spatiotemporal parameters of gait as indicators of gait quality among ambulatory persons with multiple sclerosis (MS).

DESIGN

Cross-sectional study.

SETTING

University research laboratory.

PARTICIPANTS

Community-residing persons with MS (N=268).

INTERVENTION

Not applicable.

MAIN OUTCOME MEASURES

Main outcome measures included the MSWS-12 and spatial and temporal gait parameters (walking speed, cadence, step length, step time, base of support [ie, the distance between 1 footfall and the line of progression of the opposing foot], and percentage of gait cycle spent in double support). Secondary outcomes included the timed 25-foot walk (T25FW), 6-minute walk (6MW), and Patient-Determined Disease Steps scale.

RESULTS

MSWS-12 scores were significantly correlated with walking speed (r=-.59), cadence (r=-.50), step length (r=-.53), step time (r=.46), base of support (r=.29), and percentage of the gait cycle spent in double support (r=.54). MSWS-12 scores further were significantly correlated with T25FW (r=.57) and 6MW (r=-.75) scores.

CONCLUSIONS

Such findings suggest that the MSWS-12 captures aspects of walking quality, assessed as spatiotemporal parameters of gait, in addition to walking speed and endurance in persons with MS.

摘要

目的

研究多发性硬化行走量表-12 (MSWS-12)评分与步态时空参数之间的关系,这些参数是衡量多发性硬化症患者步行质量的指标。

设计

横断面研究。

地点

大学研究实验室。

参与者

居住在社区的多发性硬化症患者(N=268)。

干预措施

不适用。

主要观察指标

主要观察指标包括 MSWS-12 和空间及时间步态参数(行走速度、步频、步长、步时、支撑基础[即一只脚的足印与对侧脚前进线之间的距离]和双支撑阶段占步态周期的百分比)。次要观察指标包括定时 25 英尺行走(T25FW)、6 分钟步行(6MW)和患者确定的疾病步骤量表。

结果

MSWS-12 评分与行走速度(r=-.59)、步频(r=-.50)、步长(r=-.53)、步时(r=.46)、支撑基础(r=.29)和双支撑阶段占步态周期的百分比(r=.54)呈显著相关。MSWS-12 评分还与 T25FW(r=.57)和 6MW(r=-.75)评分显著相关。

结论

这些发现表明,MSWS-12 除了测量多发性硬化症患者的行走速度和耐力外,还能捕捉到行走质量的方面,这些方面通过步态时空参数来评估。

相似文献

1
Further validation of multiple sclerosis walking scale-12 scores based on spatiotemporal gait parameters.基于时空步态参数的多发性硬化行走量表 12 评分的进一步验证。
Arch Phys Med Rehabil. 2013 Mar;94(3):575-8. doi: 10.1016/j.apmr.2012.08.214. Epub 2012 Sep 5.
2
Cognitive processing speed has minimal influence on the construct validity of Multiple Sclerosis Walking Scale-12 scores.认知加工速度对多发性硬化症步行量表 12 评分的结构效度影响很小。
J Neurol Sci. 2013 Dec 15;335(1-2):169-73. doi: 10.1016/j.jns.2013.09.024. Epub 2013 Sep 24.
3
Accelerometry as a measure of walking behavior in multiple sclerosis.加速度计作为多发性硬化症行走行为的测量手段。
Acta Neurol Scand. 2013 Jun;127(6):384-90. doi: 10.1111/ane.12036. Epub 2012 Dec 13.
4
Maximum walking speed in multiple sclerosis assessed with visual perceptive computing.利用视觉感知计算评估多发性硬化症患者的最大步行速度。
PLoS One. 2017 Dec 15;12(12):e0189281. doi: 10.1371/journal.pone.0189281. eCollection 2017.
5
Validation of scores from a telephone administered multiple sclerosis walking scale-12 in persons with multiple sclerosis.电话管理多发性硬化行走量表 12 评分在多发性硬化症患者中的验证。
Mult Scler Relat Disord. 2024 Aug;88:105715. doi: 10.1016/j.msard.2024.105715. Epub 2024 Jun 9.
6
Middle-range scores from the patient determined disease steps scale reflect varying levels of walking dysfunction in multiple sclerosis.从中程评分来看,患者确定疾病步骤量表反映了多发性硬化症患者在行走功能障碍方面存在不同程度的差异。
BMC Neurol. 2024 Oct 10;24(1):383. doi: 10.1186/s12883-024-03871-1.
7
Do depressive and anxiety symptoms influence the construct validity of Multiple Sclerosis Walking Scale-12 scores?抑郁和焦虑症状是否影响多发性硬化症行走量表-12 评分的结构效度?
Rehabil Psychol. 2024 May;69(2):129-134. doi: 10.1037/rep0000534. Epub 2024 Jan 1.
8
Turning is an important marker of balance confidence and walking limitation in persons with multiple sclerosis.转身是多发性硬化症患者平衡信心和行走受限的重要标志。
PLoS One. 2018 Jun 7;13(6):e0198178. doi: 10.1371/journal.pone.0198178. eCollection 2018.
9
Comparison of patient-reported outcomes of physical activity and accelerometry in people with multiple sclerosis and ambulatory impairment: A cross-sectional study.多发性硬化症伴活动障碍患者身体活动和加速度计患者报告结局的比较:一项横断面研究。
Mult Scler Relat Disord. 2024 May;85:105532. doi: 10.1016/j.msard.2024.105532. Epub 2024 Mar 1.
10
Accelerometry and its association with objective markers of walking limitations in ambulatory adults with multiple sclerosis.加速计及其与多发性硬化症步行受限的客观标志物在活动成年人中的关联。
Arch Phys Med Rehabil. 2010 Dec;91(12):1942-7. doi: 10.1016/j.apmr.2010.08.011.

引用本文的文献

1
Cut-points of the 6-min walk test, the six spot step test, and the timed-25-foot walk test discriminating impaired from non-impaired walking capacity in persons with Multiple sclerosis.在多发性硬化症患者中,6分钟步行测试、六点阶梯试验和25英尺定时步行测试区分步行能力受损与未受损的切点。
Mult Scler J Exp Transl Clin. 2025 Mar 27;11(1):20552173251324600. doi: 10.1177/20552173251324600. eCollection 2025 Jan-Mar.
2
Translation and validation of the multiple sclerosis walking scale 12 for the German population - the MSWS-12/D.德国人群多发性硬化症步行量表12(MSWS-12/D)的翻译与验证
Health Qual Life Outcomes. 2023 Oct 9;21(1):110. doi: 10.1186/s12955-023-02190-2.
3
A Systematic Review of the Validity and Reliability of the Patient-Determined Disease Steps Scale.
患者确定疾病阶段量表有效性和可靠性的系统评价
Int J MS Care. 2023 Jan-Feb;25(1):20-25. doi: 10.7224/1537-2073.2021-102. Epub 2022 Jul 5.
4
Evaluation of the Keeogo exoskeleton for assisting ambulatory activities in people with multiple sclerosis: an open-label, randomized, cross-over trial.评估 Keeogo 外骨骼系统对多发性硬化症患者步行活动的辅助作用:一项开放标签、随机、交叉试验。
J Neuroeng Rehabil. 2018 Dec 12;15(1):117. doi: 10.1186/s12984-018-0468-6.
5
Motor unit discharge characteristics and walking performance of individuals with multiple sclerosis.多发性硬化症患者的运动单位放电特征与步行能力
J Neurophysiol. 2018 Apr 1;119(4):1273-1282. doi: 10.1152/jn.00598.2017. Epub 2018 Jan 3.
6
Identifying an important change estimate for the Multiple Sclerosis Walking Scale-12 (MSWS-12v1) for interpreting clinical trial results.确定用于解释临床试验结果的多发性硬化步行量表12(MSWS - 12v1)的重要变化估计值。
Mult Scler J Exp Transl Clin. 2015 Aug 5;1:2055217315596993. doi: 10.1177/2055217315596993. eCollection 2015 Jan-Dec.
7
Italian validation of the 12-item multiple sclerosis walking scale.12项多发性硬化症步行量表的意大利语验证
Mult Scler Int. 2015;2015:540828. doi: 10.1155/2015/540828. Epub 2015 Mar 26.
8
Oxygen cost of walking in persons with multiple sclerosis: disability matters, but why?多发性硬化症患者行走时的氧气消耗:残疾起作用,但原因何在?
Mult Scler Int. 2014;2014:162765. doi: 10.1155/2014/162765. Epub 2014 Mar 6.
9
Accuracy of StepWatch™ and ActiGraph accelerometers for measuring steps taken among persons with multiple sclerosis.StepWatch™和ActiGraph加速度计在测量多发性硬化症患者步数方面的准确性。
PLoS One. 2014 Apr 8;9(4):e93511. doi: 10.1371/journal.pone.0093511. eCollection 2014.